Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum

doi:10.1016/0169-328X(92)90173-9

Molecular Brain Research

Volume 14, Issue 3, July 1992, Pages 186-195

https://doi.org/10.1016/0169-328X(92)90173-9 Get rights and content

Abstract

A cDNA fragment homologous to other G protein-coupled receptors was isolated from rat brain using the PCR method and demonstrated to be abundantly expressed in striatum. Using this fragment as a probe, a 2.1 kb full-length cDNA was isolated from a rat striatal cDNA library. This cDNA encodes a protein of 410 amino acids and is highly homologous to previously isolated adenosine receptor cDNAs. Expression of this cDNA in COS cells revealed high affinity (K_d = 38.6 nM) and saturable binding of the A₂ adenosine receptor-selective ligand [³H]CGS 21680. Agonist displacement profile of [³H]CGS 21680 binding was consistent with an adenosine receptor of the A₂ subtype (NECA > (R)-PIA >CPA > (S)-PIA). In situ hybridization demonstrated that rat A₂ adenosine receptor mRNA was co-expressed in the same striatal neurons as D₂ dopamine receptor mRNA, and never co-expressed with striatal D₁ dopamine receptor mRNA. Several lines of evidence have previously suggested that dopamine-induced changes in motor behavior can be modulated by adenosine analogs acting at the A₂ subtype of adenosine receptor in the forebrain. The co-expression of D₂ dopamine and A₂ adenosine receptors in a subset of striatal cells provides an anatomical basis for dopaminergic-adenosinergic interactions on motor behavior.

References (43)

S.P. Alexander et al.
The cellular localization of adenosine receptors in rat neostriatum
Neuroscience
(1989)
M.J. Durcan et al.
Evidence for adenosine A₂ receptor involvement in the hypomobility effects of adenosine analogues in mice
Eur. J. Pharmacol.
(1989)
S. Ferre et al.
Postsynaptic dopamine/adenosine interaction: I. Postsynaptic dopamine agonism and adenosine antagonism of methylxanthines in short-term reserpinized mice
Eur. J. Pharmacol.
(1991)
S. Ferre et al.
Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D₂-mediated behaviour in short-term reserpinized mice
Eur. J. Pharmacol.
(1991)
M.F. Jarvis et al.
Direct autoradiographic localization of adenosine A₂ receptors in rat brain using the A₂-selective agonist, [³H]CGS 21680
Eur. J. Pharmacol.
(1989)
C. Lemoine et al.
D₂ dopamine receptor gene expression by cholinergic neurons in the rat striatum
Neurosci. Lett.
(1990)
C. Maenhaut et al.
RDC8 codes for an adenosine A₂ receptor with physiological constitutive activity
Biochem. Biophys. Res. Commun.
(1990)
M.I. Martinez-Mir et al.
Adenosine A₂ receptors: selective localization in the human basal ganglia and alterations with disease
Neuroscience
(1991)
G.A. McPherson
Analysis of radioligand binding experiments: a collection of programs for IBM PC
J. Pharmacol. Methods
(1985)
O. Nikodijevic et al.
Characterization of the locomotor depression produced by an A₂-selective adenosine agonist
FEBS Lett.
(1990)

D.R. Sibley et al.

Regulation of transmembrane signalling by receptor phosphorylation

Cell

(1987)

S. Brene et al.

Expression of dopamine D₂ receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudateputamen

Exp. Brain Res.

(1990)

S.J. Brown et al.

Striatal A₂ receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation

Psychopharmacology

(1991)

R.F. Bruns et al.

Characterization of the A₂ adenosine receptor labeled by [³H] NECA in rat striatal neurons

Mol. Pharmacol.

(1986)

J.R. Bunzow et al.

Cloning and expression of a rat D₂ dopamine receptor cDNA

Nature

(1988)

L.I. Carlson et al.

Melatonin signal transduction in hamster brain: inhibition of adenylyl cyclase by a pertussis toxin-sensitive G protein

Endocrinology

(1989)

S. Ferre et al.

Stimulation of high-affinity adenosine A₂ receptors decreases the affinity of D₂ receptors in rat striatal membranes

B.B. Fredholm et al.

On the mechanism by which methylxanthines enhance apomorphine-induced rotation behaviour in the rat

Pharmacol. Biochem. Behav.

(1983)

K. Fuxe et al.

Action of caffeine and theophylline on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists

Med. Biol.

(1974)

C. Gerfen et al.

D₁ and D₂ dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

Science

(1990)

T.G. Heffner et al.

Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice

Psychopharmacology

(1989)

Cited by (619)

Aerobic exercise modulates the striatal Erk/MAPK signaling pathway and improves LID in a mouse model of Parkinson's disease
2024, Brain Research Bulletin
To investigate the role of the striatal extracellular signal-regulated kinase (Erk1/2) and its phosphorylation (p-Erk1/2) in aerobic training to alleviate the development of the L-DOPA induced dyskinesia (LID) in PD mice.
Forty-eight male C57BL/6 N mice were randomly divided into the 6-OHDA surgery group (6-OHDA, n=42) and the sham surgery group (Sham, n=6). A two-point injection of 6-OHDA into the right striatum was used to establish a lateralized injury PD model. PD mice were randomly divided into a PD control group (PD, n=13) and a PD exercise group (PDE, n=16), this is followed by 4 weeks of L-DOPA treatment, and PDE mice received concurrent running table training (18 m/min, 40 min/day, 5 times/week). AIM scores were performed weekly, and mice were assessed for motor function after 4 weeks using the rotarod, open field, and gait tests. Immunohistochemistry was used to test nigrostriatal TH expression, Western blot was used to determine Erk1/2 and p-Erk1/2 protein expression, and immunofluorescence double-labeling technique was used to detect Erk1/2 and p-Erk1/2 co-expression with prodynorphin (PDYN).
(1) All AIM scores of PD and PDE mice increased significantly (P < 0.05) with the prolongation of L-DOPA treatment. Compared with PD, all AIM scores were significantly lower in PDE mice (P < 0.05). (2) After 4 weeks, the motor function of PD mice was significantly reduced compared with Sham (P < 0.05 or P < 0.01); compared with PD, the motor function of PDE mice was significantly increased (P < 0.05). (3) Compared with Sham, the expression of Erk1/2 protein, the number of positive cells of Erk1/2 and p-Erk1/2 and the number of positive cells co-expressed with PDYN were significantly increased in PD mice (P < 0.05); compared with PD, Erk1/2 protein expression was significantly decreased in PDE mice (P < 0.05), and the number of Erk1/2 and p-Erk1/2 positive cells was significantly reduced (P < 0.05).
4 weeks of aerobic exercise can effectively alleviate the development of L-DOPA-induced dyskinesia and improve motor function in PD mice. The related mechanism may be related to the inhibition of striatal Erk/MAPK signaling pathway overactivation by aerobic exercise, but this change did not occur selectively in D₁-MSNs.
Using caffeine as a chemical means to induce flow states
2024, Neuroscience and Biobehavioral Reviews
Flow is an intrinsically rewarding state characterised by positive affect and total task absorption. Because cognitive and physical performance are optimal in flow, chemical means to facilitate this state are appealing. Caffeine, a non-selective adenosine receptor antagonist, has been emphasized as a potential flow-inducer. Thus, we review the psychological and biological effects of caffeine that, conceptually, enhance flow. Caffeine may facilitate flow through various effects, including: i) upregulation of dopamine D1/D2 receptor affinity in reward-associated brain areas, leading to greater energetic arousal and ‘wanting’; ii) protection of dopaminergic neurons; iii) increases in norepinephrine release and alertness, which offset sleep-deprivation and hypoarousal; iv) heightening of parasympathetic high frequency heart rate variability, resulting in improved cortical stress appraisal, v) modification of striatal endocannabinoid-CB1 receptor-signalling, leading to enhanced stress tolerance; and vi) changes in brain network activity in favour of executive function and flow. We also discuss the application of caffeine to treat attention deficit hyperactivity disorder and caveats. We hope to inspire studies assessing the use of caffeine to induce flow.
Prenatal exposition to haloperidol: A preclinical narrative review
2023, Neuroscience and Biobehavioral Reviews
Pre-existing maternal mental disorders may affect the early interactions between mother and baby, impacting the child’s psychoemotional development. The typical antipsychotic haloperidol can be used during pregnancy, even with some restrictions. Its prescription is not limited to psychotic disorders, but also to other psychiatric conditions of high incidence and prevalence in the woman's fertile period. The present review focused on the preclinical available data regarding the biological and behavioral implications of embryonic exposure to haloperidol. The understanding of the effects of psychotropic drugs during neurodevelopment is important for its clinical aspect since there is limited evidence regarding the risks of antipsychotic drug treatment in pregnant women and their children. Moreover, a better comprehension of the mechanistic events that can be affected by antipsychotic treatment during the critical period of neurodevelopment may offer insights into the pathophysiology of neurodevelopmental disorders. The findings presented in this review converge to the existence of several risks associated with prenatal exposure to such medication and emphasize the need for further studies regarding its dimensions.
Role of adenosine A2A receptors in hot and cold cognition: Effects of single-dose istradefylline in healthy volunteers
2023, European Neuropsychopharmacology
The role of the adenosine neurochemical system in human cognition is under-studied, despite such receptors being distributed throughout the brain. The aim of this study was to shed light on the role of the adenosine A2A receptors in human cognition using single-dose istradefylline. Twenty healthy male participants, aged 19–49, received 20 mg istradefylline and placebo, in a randomized, double-blind, placebo-controlled cross-over design. Cognition was assessed using computerized cognitive tests, covering both cold (non-emotional) and hot (emotion-laden) domains. Cardiovascular data were recorded serially. Cognitive effects of istradefylline were explored using repeated measures analysis of variance and paired t-tests as appropriate. On the EMOTICOM battery, there was a significant effect of istradefylline versus placebo on the Social Information Preference task (t = 2.50, p = 0.02, d=-0.59), indicating that subjects on istradefylline interpreted social situations more positively. No other significant effects were observed on other cognitive tasks, nor in terms of cardiovascular measures (pulse and blood pressure). De-briefing indicated that blinding was successful, both for participants and the research team. Further exploration of the role of adenosine A2A receptors in emotional processing may be valuable, given that abnormalities in related cognitive functions are implicated in neuropsychiatric disorders. The role of adenosine systems in human cognition requires further clarification, including with different doses of istradefylline and over different schedules of administration.
The adenosine A<inf>2A</inf> receptor in the basal ganglia: Expression, heteromerization, functional selectivity and signalling
2023, International Review of Neurobiology
Adenosine is a neuroregulatory nucleoside that acts through four G protein-coupled receptors (GPCRs), A₁, A_2A, A_2B and A₃, which are widely expressed in cells of the nervous system. The A_2A receptor (A_2AR), the GPCR with the highest expression in the striatum, has a similar role to that of receptors for dopamine, one of the main neurotransmitters. Neuronal and glial A_2ARs participate in the modulation of dopaminergic transmission and act in almost any action in which the basal ganglia is involved. This chapter revisits the expression of the A_2AR in the basal ganglia in health and disease, and describes the diversity of signalling depending on whether the receptors are expressed as monomer or as heteromer. The A_2AR can interact with other receptors as adenosine A₁, dopamine D₂, or cannabinoid CB₁ to form heteromers with relevant functions in the basal ganglia. Heteromerization, with these and other GPCRs, provides diversity to A_2AR-mediated signalling and to the modulation of neurotransmission. Thus, selective A_2AR antagonists have neuroprotective potential acting directly on neurons, but also through modulation of glial cell activation, for example, by decreasing neuroinflammatory events that accompany neurodegenerative diseases. In fact, A_2AR antagonists are safe and their potential in the therapy of Parkinson’s disease has already led to the approval of one of them, istradefylline, in Japan and United States. The receptor also has a key role in reward circuits and, again, heteromers with dopamine receptors, but also with cannabinoid CB₁ receptors, participate in the events triggered by drugs of abuse.
Novel therapeutic interventions for combating Parkinson's disease and prospects of Nose-to-Brain drug delivery
2022, Biochemical Pharmacology
Parkinson disease (PD) is a progressive neurodegenerative disorder prevalent mainly in geriatric population. While, L-DOPA remains one of the major choices for the therapeutic management of PD, various motor and non-motor manifestations complicate the management of PD. In the last two decades, exhaustive research has been carried out to explore novel therapeutic approaches for mitigating motor and non-motor symptoms of PD. These approaches majorly include receptor-based, anti-inflammatory, stem-cell and nucleic acid based. The major limitations of existing therapeutic interventions (of commonly oral route) are low efficacy due to low brain bioavailability and associated side effects. Nanotechnology has been exploited and has gained wide attention in the recent years as an approach for enhancement of bioavailability of various small molecule drugs in the brain. To address the challenges associated with PD therapy, nose-to-brain delivery utilizing nanomedicine-based approaches has been found to be encouraging in published evidence. Therefore, the present work summarises the major challenges and limitations with antiparkinsonian drugs, novel therapeutic interventions, and scope of nanomedicine-based nose-to-brain delivery in addressing the current challenges of antiparkinsonian therapy. The manuscript tries to sensitize the researchers for designing brain-targeted nanomedicine loaded with natural/synthetic scaffolds, biosimilars, and nucleic acids that can bypass the first-pass effect for the effective management of PD.

View all citing articles on Scopus

View full text

Research reportMolecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum

Abstract

Neuroscience

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Eur. J. Pharmacol.

Neurosci. Lett.

Biochem. Biophys. Res. Commun.

Neuroscience

J. Pharmacol. Methods

FEBS Lett.

Cell

Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudateputamen

Exp. Brain Res.

Striatal A2 receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation

Psychopharmacology

Characterization of the A2 adenosine receptor labeled by [3H] NECA in rat striatal neurons

Mol. Pharmacol.

Cloning and expression of a rat D2 dopamine receptor cDNA

Nature

Melatonin signal transduction in hamster brain: inhibition of adenylyl cyclase by a pertussis toxin-sensitive G protein

Endocrinology

Stimulation of high-affinity adenosine A2 receptors decreases the affinity of D2 receptors in rat striatal membranes

On the mechanism by which methylxanthines enhance apomorphine-induced rotation behaviour in the rat

Pharmacol. Biochem. Behav.

Action of caffeine and theophylline on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists

Med. Biol.

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

Science

Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice

Psychopharmacology

Research report
Molecular cloning of the rat A₂ adenosine receptor: selective co-expression with D₂ dopamine receptors in rat striatum

Expression of dopamine D₂ receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudateputamen

Striatal A₂ receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation

Characterization of the A₂ adenosine receptor labeled by [³H] NECA in rat striatal neurons

Cloning and expression of a rat D₂ dopamine receptor cDNA

Stimulation of high-affinity adenosine A₂ receptors decreases the affinity of D₂ receptors in rat striatal membranes

D₁ and D₂ dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons